Clinical Trial Update: A Study of the Histone-deacetylase Inhibitor JNJ-26481585 in Patients With Advanced or Refractory Leukemia or Myelodysplastic Syndrome [Phase 1]

View source ↗

Summary

Phase 1 study of the histone-deacetylase inhibitor JNJ-26481585 in patients with advanced or refractory leukemia or myelodysplastic syndromes has been terminate…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia
• Myelodysplastic Syndromes

Drugs mentioned

• JNJ-26481585

Snippet

Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Conditions: Advanced or Refractory Leukemia, Myelodysplastic Syndromes | Phase 1 | Status: TERMINATED